Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer

Breast. 2021 Dec 13:S0960-9776(21)01014-6. doi: 10.1016/j.breast.2021.12.008. Online ahead of print.ABSTRACTCDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site of metastasis, CDK4/6 inhibitor used and associated endocrine therapy. A benefit in overall survival has also been demonstrated. In early breast cancer, only the MonarchE study has shown an improved invasive disease-free survival with abemaciclib taken for 2 years, whereas the Penelope-B did not meet the primary endpoint and the PALLAS study was terminated early for futility. Studies conducted in the neoadjuvant setting might help to explain the discordant results.PMID:34930649 | DOI:10.1016/j.breast.2021.12.008
Source: Breast - Category: Cancer & Oncology Authors: Source Type: research